<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1006">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712175</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL-COVID/2020/AS-01</org_study_id>
    <nct_id>NCT04712175</nct_id>
  </id_info>
  <brief_title>Diagnostic Validation of Rapid Detection of the COVID-19 Causative Virus (SARS-CoV-2) in Saliva Samples by Mass Spectrometry</brief_title>
  <acronym>SALICOV</acronym>
  <official_title>Validation Diagnostique de la détection Rapide du Virus SARS-CoV-2 Dans Des échantillons Salivaires Par spectrométrie de Masse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technological Innovations for Detection and Diagnosis Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to control the COVID-19 pandemic, a policy for the diagnosis and screening of people&#xD;
      likely to be infected with SARS-CoV-2 has been established The reference diagnostic test is&#xD;
      RT-PCR on nasopharyngeal swab. Nasopharyngeal swabbing requires training, generates a risk of&#xD;
      aerosolization and therefore viral transmission to the operator, and is unpleasant or even&#xD;
      painful for the patient. RT-PCR is efficient, but time-consuming. It is therefore necessary&#xD;
      to consider techniques that are less subject to difficulties of production and sampling, and&#xD;
      less time-consuming. Tandem mass spectrometry on saliva samples is a promising option. A&#xD;
      combined &quot;mass spectrometry/saliva test&quot; should provide faster results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of SARS-CoV-2 on nasopharyngeal samples (gold standard)</measure>
    <time_frame>Day 0</time_frame>
    <description>RT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of SARS-CoV-2 on a saliva samples by mass spectrometry</measure>
    <time_frame>Day 0</time_frame>
    <description>tandem mass spectrometry test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of SARS-CoV-2 on saliva samples via RT-PCR</measure>
    <time_frame>Day 0</time_frame>
    <description>RT-PCR</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Patients with SARS-CoV-2 infection</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without SARS-CoV-2 infection</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasopharyngeal sampling</intervention_name>
    <description>Swabs will be taken of nasopharyngeal samples for RT-PCR</description>
    <arm_group_label>Patients with SARS-CoV-2 infection</arm_group_label>
    <arm_group_label>Patients without SARS-CoV-2 infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Saliva sampling</intervention_name>
    <description>A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR</description>
    <arm_group_label>Patients with SARS-CoV-2 infection</arm_group_label>
    <arm_group_label>Patients without SARS-CoV-2 infection</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Anonymized saliva samples of patients with positive RT-PCR results.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults presenting to the Walk-in Center for Emerging Biological Risks of the Nîmes&#xD;
        University Hospital for screening for SARS-CoV-2 infection or who are hospitalized at the&#xD;
        Infectious and Tropical Diseases Department for severe infection with SARS-CoV-2.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must not have opposed their inclusion in the study&#xD;
&#xD;
          -  Patient presenting to the Walk-in Center for Emerging Biological Risks for SARS-CoV-2&#xD;
             screening by nasopharyngeal swab OR hospitalized in the Infectious and Tropical&#xD;
             Diseases Department for severe SARS-CoV-2 infection, diagnosed by RT-PCR on&#xD;
             nasopharyngeal sample, taken at Nîmes University Hospital, in the previous 24 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient already included in the study&#xD;
&#xD;
          -  The subject is in a period of exclusion determined by a previous study&#xD;
&#xD;
          -  It is impossible to give the subject clear information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  Patient unable to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Sotto</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albert Sotto</last_name>
    <phone>04.66.68.41.49</phone>
    <email>albert.sotto@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Albert Sotto</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Loubet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Laureillard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe Lavigne</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Armengaud</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucia Grenga</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gouveia D, Miotello G, Gallais F, Gaillard JC, Debroas S, Bellanger L, Lavigne JP, Sotto A, Grenga L, Pible O, Armengaud J. Proteotyping SARS-CoV-2 Virus from Nasopharyngeal Swabs: A Proof-of-Concept Focused on a 3 Min Mass Spectrometry Window. J Proteome Res. 2020 Nov 6;19(11):4407-4416. doi: 10.1021/acs.jproteome.0c00535. Epub 2020 Aug 5.</citation>
    <PMID>32697082</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

